2026 Outsourcing Outlook Update - pharma at a crossroads

The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing capabilities. Read all about it in the CPHI Online 2026 Outsourcing Outlook Update: Navigating Global Innovation.

The comprehensive industry report highlights five major trends reshaping pharmaceutical outsourcing relationships and manufacturing strategies worldwide.

The Great Bifurcation: Specialisation vs. Integration

The pharmaceutical manufacturing landscape is witnessing a significant bifurcation between high-value, specialised production and large-scale, commoditised operations. As advanced therapeutics like cell and gene therapies demand precision and innovation, manufacturers are increasingly focusing on niche capabilities whilst traditional pharmaceutical production continues to scale globally.

"We are witnessing a significant shift towards specialised manufacturing partners across various levels of the industry," said Ashley Cox, CEO and Founder of Caledonia Life Sciences. "CDMOs offer greater cost and time efficiency by streamlining processes and reducing handoffs between different stages."

However, the appeal of fully integrated, end-to-end CDMOs continues to strengthen as pharmaceutical companies seek fewer, more strategic partners who can carry assets seamlessly from development through commercial manufacturing.

Strategic Partnerships Mature with Robust Governance

The report emphasises that strategic partnerships in pharma are evolving beyond transactional relationships, with governance structures becoming critical to success. Mature partnerships now leverage formal, multi-tier governance frameworks including joint steering committees, mid-level management teams, and operational working groups.

"Long-term pharma-CDMO partnerships increasingly use formal, multi-tier governance as opposed to ad hoc oversight," explained Bikash Chatterjee, President and Chief Science Officer at Pharmatech Associates. "These structures are underpinned by quality agreements and master service agreements with structured communication routines to maintain transparency and joint accountability."

Geopolitical Pressures Reshape Supply Chains

Global supply chains face mounting pressure as geopolitical tensions disrupt upstream operations. The report reveals that trade restrictions, regional conflicts, and shifting alliances are creating bottlenecks in raw materials and active pharmaceutical ingredient (API) availability.

"Geopolitics is hitting the upstream parts of the pharma supply chain hardest, especially APIs, key starting materials, and bioprocessing inputs that are heavily concentrated in a few countries," noted Chatterjee. Companies are re-evaluating sourcing strategies, prioritising diversification and nearshoring to mitigate risks.

The shift towards nearshoring represents a strategic pivot from pure cost-optimisation to supply chain resilience, with the US CDMO market projected to grow from US$43.41 billion in 2025 to over US$83 billion by 2034—a compound annual growth rate of 7.47%.

Private Equity Drives M&A Activity

Private equity-backed transactions and mergers and acquisitions in the CDMO sector are reshaping the pharmaceutical landscape. PE firms are driving consolidation, seeking to optimise operations and expand capabilities to meet growing demand for specialised services.

The report notes that M&A activities are experiencing resurgence in 2026, driven by intensified therapeutic focus, premiums for innovation, and opportunities for cross-border collaborations, with deals increasingly focusing on acquiring capabilities in advanced drug modalities, cell and gene therapies, and radiopharmaceuticals.

AI-Driven Partnerships Gain Momentum

Artificial intelligence is revolutionising pharma partnerships, enabling smarter collaboration and faster decision-making. AI-driven partnerships are gaining traction as companies leverage advanced analytics to optimise drug development, manufacturing, and supply chain operations.

"Pharmaceutical sponsors and vendors are increasingly integrating AI into drug discovery and automating manufacturing processes," said Joon Ho Hwang, Vice President of Business Strategy at Samsung Biologics. "By employing predictive algorithms and deep learning, companies can identify high-potential drug candidates more efficiently, significantly reducing the development timeline."

Capacity Expansion Focuses on High-Value Niches

The report reveals that capacity expansion is being driven by genuine demand signals in high-value niches such as cell and gene therapies, complex injectables, and high-containment modalities, which still show structural undersupply. CDMOs are adding highly specialised, technology-forward capacity that explicitly targets pipeline complexity and platform differentiation.

"Customers are increasingly wary of capacity that isn't aligned with projected future demand, particularly in complex areas like HPAPIs and ADCs, where execution matters as much as infrastructure," stated Arul Ramadurai, Chief Commercial Officer at Axplora.

Looking Ahead

As the pharmaceutical outsourcing landscape continues to evolve, the report emphasises that success will depend on CDMOs' and sponsors' ability to balance cost efficiency with supply chain resilience, leverage strategic partnerships with robust governance, and invest in specialised capabilities that align with future therapeutic demands.

The 2026 Outsourcing Outlook Update: Navigating Global Innovation provides comprehensive insights into the trends shaping pharmaceutical outsourcing and offers strategic guidance for industry stakeholders navigating this complex and dynamic environment.

Download the full report below.